Granulomatosis with Polyangiitis (GPA) is a systemic vasculitis characterized by upper and lower respiratory tract involvement with renal manifestations. Bronchiolitis Obliterans Organizing Pneumonia (BOOP) can be a misleading pulmonary manifestation especially in the onset of the disease, in the absence of the other major findings of GPA which can develop later during the follow up. Malignancy occurrence seems to be increased in GPA patients due to treatment but other authors reported an increase of preceding cancers too. We reported a case of BOOP in the onset of GPA associated with orbital pseudo tumor and prostatic cancer.
{"title":"Bronchiolitis Obliterans Organizing Pneumonia on the Onset of Granulomatosis with Polyangiitis Associated with Orbital Involvement and Prostatic Carcinoma","authors":"M. Kechida, Imen Khairallah Ksiaa, Rhouma Kb, N. Zaafrane, S. Khochtali, M. Khairallah","doi":"10.16966/2470-3176.134","DOIUrl":"https://doi.org/10.16966/2470-3176.134","url":null,"abstract":"Granulomatosis with Polyangiitis (GPA) is a systemic vasculitis characterized by upper and lower respiratory tract involvement with renal manifestations. Bronchiolitis Obliterans Organizing Pneumonia (BOOP) can be a misleading pulmonary manifestation especially in the onset of the disease, in the absence of the other major findings of GPA which can develop later during the follow up. Malignancy occurrence seems to be increased in GPA patients due to treatment but other authors reported an increase of preceding cancers too. We reported a case of BOOP in the onset of GPA associated with orbital pseudo tumor and prostatic cancer.","PeriodicalId":91749,"journal":{"name":"Journal of infectious pulmonary diseases","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67392679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The incidence and severity of asthma continue to rise worldwide. β-agonists are the most commonly prescribed therapeutic for asthma management but have less efficacy for some subsets of asthmatic patients and there are concerns surrounding the side effects from their long-term persistent use. The demand to develop novel asthma therapeutics highlights the need for a standardized approach to effectively screen and test potential bronchoprotective compounds using relevant in vivo animal models. Here we describe a validated method of testing potential therapeutic compounds for their fast-acting efficacy during the midst of an induced bronchoconstriction in a house dust mite challenged animal model.
{"title":"A Novel <i>in vivo</i> System to Test Bronchodilators.","authors":"Kenneth J Addison, John Morse, Annette Robichaud, Michael O Daines, Julie G Ledford","doi":"10.16966/2470-3176.120","DOIUrl":"https://doi.org/10.16966/2470-3176.120","url":null,"abstract":"<p><p>The incidence and severity of asthma continue to rise worldwide. β-agonists are the most commonly prescribed therapeutic for asthma management but have less efficacy for some subsets of asthmatic patients and there are concerns surrounding the side effects from their long-term persistent use. The demand to develop novel asthma therapeutics highlights the need for a standardized approach to effectively screen and test potential bronchoprotective compounds using relevant <i>in vivo</i> animal models. Here we describe a validated method of testing potential therapeutic compounds for their fast-acting efficacy during the midst of an induced bronchoconstriction in a house dust mite challenged animal model.</p>","PeriodicalId":91749,"journal":{"name":"Journal of infectious pulmonary diseases","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5375107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34877357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chronic pulmonary disease and infection is the primary cause of morbidity and mortality in people with cystic fibrosis (CF). Though Pseudomonas aeruginosa, is most commonly found in the airways of individuals with CF, there is increasing appreciation for the diversity of the CF microbiome, including other taxa such as Bordetella. Here we describe the identification and impact of Bordetella pseudohinzii infection in CF mice, which previously have not been thought to develop spontaneous airway infections. We determined that CF mice are more susceptible to the B. pseudohinzii infections, and less able to resolve the infection than non-CF mice. Moreover, in both CF and non-CF mice, B. pseudohinzii infections lead to markedly reduced respiratory rates and a CF-specific immune response. These results establish the CF mouse model as an important tool for the study of CF-relevant infection and highlight the potential contribution of Bordetella to CF clinical pathology.
{"title":"Cystic Fibrosis Mice Develop Spontaneous Chronic <i>Bordetella</i> Airway Infections.","authors":"R Darrah, T Bonfield, J J LiPuma, P Litman, C A Hodges, F Jacono, M Drumm","doi":"10.16966/2470-3176.128","DOIUrl":"https://doi.org/10.16966/2470-3176.128","url":null,"abstract":"Chronic pulmonary disease and infection is the primary cause of morbidity and mortality in people with cystic fibrosis (CF). Though Pseudomonas aeruginosa, is most commonly found in the airways of individuals with CF, there is increasing appreciation for the diversity of the CF microbiome, including other taxa such as Bordetella. Here we describe the identification and impact of Bordetella pseudohinzii infection in CF mice, which previously have not been thought to develop spontaneous airway infections. We determined that CF mice are more susceptible to the B. pseudohinzii infections, and less able to resolve the infection than non-CF mice. Moreover, in both CF and non-CF mice, B. pseudohinzii infections lead to markedly reduced respiratory rates and a CF-specific immune response. These results establish the CF mouse model as an important tool for the study of CF-relevant infection and highlight the potential contribution of Bordetella to CF clinical pathology.","PeriodicalId":91749,"journal":{"name":"Journal of infectious pulmonary diseases","volume":"3 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36555496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The devastating synergism of bacterial pneumonia with influenza viral infections left its mark on the world over the last century. Although the details of pathogenesis remain unclear, the synergism is related to a variety of factors including pulmonary epithelial barrier damage which exposes receptors that influence bacterial adherence and the triggering of an exaggerated innate immune response and cytokine storm, which further acts to worsen the injury. Several therapeutics and combination therapies of antibiotics, anti-inflammatories including corticosteroids and toll-like receptor modifiers, and anti-virals are being discussed. This mini review summarizes recent developments in unearthing the pathogenesis of the lethal synergism of pneumococcal co-infection following influenza, as well as addresses potential therapeutic options and combinations of therapies currently being evaluated.
{"title":"Lethal Synergism between Influenza and Streptococcus pneumoniae","authors":"Jennifer M. Rudd, Harshini K. Ashar, V. Chow, N. Teluguakula","doi":"10.16966/2470-3176.114","DOIUrl":"https://doi.org/10.16966/2470-3176.114","url":null,"abstract":"The devastating synergism of bacterial pneumonia with influenza viral infections left its mark on the world over the last century. Although the details of pathogenesis remain unclear, the synergism is related to a variety of factors including pulmonary epithelial barrier damage which exposes receptors that influence bacterial adherence and the triggering of an exaggerated innate immune response and cytokine storm, which further acts to worsen the injury. Several therapeutics and combination therapies of antibiotics, anti-inflammatories including corticosteroids and toll-like receptor modifiers, and anti-virals are being discussed. This mini review summarizes recent developments in unearthing the pathogenesis of the lethal synergism of pneumococcal co-infection following influenza, as well as addresses potential therapeutic options and combinations of therapies currently being evaluated.","PeriodicalId":91749,"journal":{"name":"Journal of infectious pulmonary diseases","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67393072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}